Literature DB >> 19711487

Generation of a syngeneic mouse model to study the intraperitoneal dissemination of ovarian cancer with in vivo luciferase imaging.

Masafumi Toyoshima1, Yoshinori Tanaka, Mitsuyo Matumoto, Miyuki Yamazaki, Satoru Nagase, Kazuo Sugamura, Nobuo Yaegashi.   

Abstract

In order to facilitate the discovery and investigation of anti-cancer therapeutics under physiological conditions, we have engineered the ovarian cancer cell line, HM-1/luc, in mice. This cell stably expresses firefly luciferase and produces light that can be detected using an in vivo imaging system (IVIS). Parental HM-1 cells cause severe carcinomatous peritonitis to B6C3F1 mice, but not to C57BL6 mice. Established HM-1/luc cells showed pathologically similar findings to HM-1 cells. HM-1/luc cells were injected into the peritoneal cavity of B6C3F1 mice and IVIS 2000 was conducted weekly after inoculation to monitor intra-peritoneal tumor growth. The mice were divided into three groups: non-CDDP-treated (control) and CDDP-treated (0.2 and 0.4 mg). A disease-suppressive effect of the CDDP was reflected by the significantly prolonged survival of the CDDP-treated mice (control 23 +/- 1.9 days, CDDP 0.2 mg 29.6 +/- 2.9 days; p < 0.05); the total photon and area of flux were decreased. The optical imaging of intraperitoneal tumors via in vivo bioluminescence is effective for noninvasive monitoring and semi-quantitative analysis. Our syngeneic mouse model has the relevant clinical features of ovarian cancer, which makes it a useful model for developing new ovarian cancer therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19711487     DOI: 10.1002/bio.1112

Source DB:  PubMed          Journal:  Luminescence        ISSN: 1522-7235            Impact factor:   2.464


  10 in total

1.  Development of a syngeneic mouse model of epithelial ovarian cancer.

Authors:  Bridget A Quinn; Fang Xiao; Laura Bickel; Lainie Martin; Xiang Hua; Andres Klein-Szanto; Denise C Connolly
Journal:  J Ovarian Res       Date:  2010-10-19       Impact factor: 4.234

2.  Intraperitoneal photodynamic therapy mediated by a fullerene in a mouse model of abdominal dissemination of colon adenocarcinoma.

Authors:  Pawel Mroz; Yumin Xia; Daisuke Asanuma; Aaron Konopko; Timur Zhiyentayev; Ying-Ying Huang; Sulbha K Sharma; Tianhong Dai; Usman J Khan; Tim Wharton; Michael R Hamblin
Journal:  Nanomedicine       Date:  2011-05-19       Impact factor: 5.307

3.  Gene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis.

Authors:  Rie Natatsuka; Tsuyoshi Takahashi; Satoshi Serada; Minoru Fujimoto; Tomohiro Ookawara; Toshirou Nishida; Hisashi Hara; Takahiko Nishigaki; Emi Harada; Takashi Murakami; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Makoto Yamasaki; Hiroshi Miyata; Kiyokazu Nakajima; Shuji Takiguchi; Tadamitsu Kishimoto; Masaki Mori; Yuichiro Doki; Tetsuji Naka
Journal:  Br J Cancer       Date:  2015-07-16       Impact factor: 7.640

4.  Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer.

Authors:  John B Liao; Kelsie J Ovenell; Erin E M Curtis; Denise L Cecil; Marlese R Koehnlein; Lauren R Rastetter; Ekram A Gad; Mary L Disis
Journal:  J Immunother Cancer       Date:  2015-05-19       Impact factor: 13.751

5.  Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay.

Authors:  Ryo Takahashi; Takehiko Yokobori; Katsuya Osone; Hironori Tatsuki; Takahiro Takada; Toshinaga Suto; Reina Yajima; Toshihide Kato; Takaaki Fujii; Souichi Tsutsumi; Hiroyuki Kuwano; Takayuki Asao
Journal:  Cancer Sci       Date:  2016-02-09       Impact factor: 6.716

6.  Use of Transabdominal Ultrasound for the detection of intra-peritoneal tumor engraftment and growth in mouse xenografts of epithelial ovarian cancer.

Authors:  Laura M Chambers; Emily Esakov; Chad Braley; Mariam AlHilli; Chad Michener; Ofer Reizes
Journal:  PLoS One       Date:  2020-04-29       Impact factor: 3.240

7.  Pretreatment with LCK inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors.

Authors:  Katie K Crean-Tate; Chad Braley; Goutam Dey; Emily Esakov; Caner Saygin; Alexandria Trestan; Daniel J Silver; Soumya M Turaga; Elizabeth V Connor; Robert DeBernardo; Chad M Michener; Peter G Rose; Justin Lathia; Ofer Reizes
Journal:  J Ovarian Res       Date:  2021-04-22       Impact factor: 4.234

8.  Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model.

Authors:  Simone Pisano; Stefania Lenna; Gareth D Healey; Fereshteh Izardi; Lucille Meeks; Yajaira S Jimenez; Oscar S Velazquez; Deyarina Gonzalez; Robert Steven Conlan; Bruna Corradetti
Journal:  Clin Transl Med       Date:  2021-10

Review 9.  Recent technological advances in using mouse models to study ovarian cancer.

Authors:  Carrie Danielle House; Lidia Hernandez; Christina Messineo Annunziata
Journal:  Front Oncol       Date:  2014-02-13       Impact factor: 6.244

10.  Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.

Authors:  Yuko Tanizaki; Aya Kobayashi; Saori Toujima; Michihisa Shiro; Mika Mizoguchi; Yasushi Mabuchi; Shigetaka Yagi; Sawako Minami; Osamu Takikawa; Kazuhiko Ino
Journal:  Cancer Sci       Date:  2014-06-27       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.